Stability testing

Stability testing is performed after storage in defined conditions according to standard and accelerated ICH conditions. We provide you with different range of storage conditions. All storage rooms are fully-controlled with 24/7 monitoring and alert systems.

Our services include:

  • Support in designing studies for real-time
  • Development and validation of “stability indicating methods”
  • Examination of stability-relevant parameters (temperature – humidity)
  • Interim reports for every testing period
  • Comprehensive final report

Looking for clinical advice or support, or preparing for a clinical study? We will help you set up a cost-effective and time-efficient study! Get in touch with our experts [info@b2h.be].

Protein misfolding & aggregation

Researchers at CIP use a multi-angle approach to investigate mechanisms by which soluble amyloidogenic proteins (including: human lysozyme, alpha-synuclein and polyglutamine proteins) assemble into amyloid fibrils.

Their original approach to identify and characterize these proteins in terms of structure, stability, kinetic of formation and toxicity involves:

  • The generation of heavy-chain antibody fragments (also referred as Nanobodies) specific of the amyloidogenic proteins that can be used (i) as structural probes and (ii) as potential inhibitor of the aggregation process
  • The creation of chimeric proteins composed of the beta-lactamase BlaP and amyloidogenic peptides to investigate the role of the amyloid stretches in the process of aggregation and to generate antibodies against specific amyloidogenic peptides

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

AMPA potentiators

The AMPA subtype of glutamatergic receptors is the main actor in the excitatory neurotransmission in the mammalian central nervous system. These receptors are involved in the expression and the maintenance of the long-term potentiation, a phenomenon closely linked to cognitive and memorization processes.

Based on experimental data collected in recent years, the use of AMPA potentiators seems to be an interesting approach in the treatment of cognitive deficits (e.g. Alzheimer’s disease), schizophrenia or depression. Such AMPA signal potentiation could be mediated by positive allosteric modulators (PAMs) of the AMPA receptors, a class of compounds able to produce a fine signal tuning in the presence of the endogenous ligand in the synapse, providing less toxicity than direct agonists.
With this approach, the University of Liège developed many series of AMPA potentiators, among which 1,2,4-benzothiadiazine 1,1-dioxides (BTDs). The team is currently developing BTDs positive allosteric modulator radiolabeled with a fluorin-18 atom that can potentially be used in a clinical setting. For more information, click here.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Thiamine & neuronal death prevention

Researchers at GIGA have a large expertise in the analysis of thiamine compounds. Few years ago, they have discovered a new thiamine derivative: the adenosine thiamine triphosphate.

Their current research focuses on the use of thiamine and its precursors as therapeutic agents in neurodegenerative diseases due to their high bioavailability. More particularly, they aim at identifying the pharmacologically active thiamine compound and investigating its mechanisms of action.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Potassium channel modulators

The new compounds based on disubstituted anilines, by opening potassium channels, can be used for the treatment of vasospastic disorders (i.e. subarachnoid hemorrhage and migraine), of various diseases of the central nervous system (i.e. epilepsy, ischemia and neurodegenerative diseases) as well as pain treatment.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Calcium-activated potassium channel modulators

Small conductance calcium-activated potassium (SK, KCa2) channels represent interesting and challenging targets in medicinal chemistry. So far, the reference ligand is apamin, a peptide including the [125I] analog for binding studies. Nonpeptidic ligands with high affinity have been developed for several years. Currently, different questions remain to be solved since no selective and brain-penetrating agent is available. In addition, replacing [125I]apamin in binding experiments would be also interesting.

Researchers at CIRM have developed different series of compounds exhibiting significant affinity for SK channels.

These new compounds may act as SK channels blockers or may interact selectively with one of the three subtypes (i.e. SK1, SK2, SK3) offering a novel approach to the treatment of CNS diseases (i.e. Alzheimer’s disease, Parkinson’s disease, neurodegenerative disorders, psychotic disorders, cognitive dysfunction, alcohol and drug addiction, depression…).

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Drug administration & Patient monitoring

Picture_Logo_ATC

  • Centralized clinical unit with 30 equipped hospital beds
  • Experience in running different study types and trial design
  • Different types of drugs like NCE and NBE
  • Database of more than 2.700 healthy and reliable volunteers
  • Privileged access to medical and technical expertise of CHU and ULg (such as Cyclotron, GIGA, CIP, Sleep Center, Pain clinic…)

We offer you a professional and scientific support to conduct clinical trials and the decision making processes during the early phases of the development of new molecules. This includes clinical pharmacology trials giving an insight into a drug candidate’s safety, tolerability, pharmacokinetics and pharmacodynamics.

Looking for clinical advice or support, or preparing for a clinical study? We will help you set up a cost-effective and time-efficient study! Get in touch with our experts [info@b2h.be].


Induced pluripotent stem cells

Due to the close association with the CHU de Liège, GIGA researchers have access to fibroblasts of patients. They have developed a large expertise in the generation of induced pluripotent stem cells, their characterization and differentiation into specialized neuronal cells in vitro.

Contact [info@b2h.be] us to discuss how these capabilities can forward your projects! We will help you develop tailored solutions.

Stem Cells

Teams at GIGA are specialized in the investigations of stem cells (including mesenchymal stem cells and neural crest stem cells) biology, purification and expansion, as well as in their therapeutic use in the context of regenerative medicine.

Contact [info@b2h.be] us to discuss how these capabilities can forward your projects! We will help you develop tailored solutions.

Novel pharmaceutical formulations

Researchers at ULg have a broad expertise in the development of novel pharmaceutical formulations to improve the solubility and the bioavailability of compounds and to facilitate drug delivery to brain cells.

To test these new formulations, they have also developed a cellular blood brain barrier model using immortalized human cerebral microvascular endothelial cells.

For more information, click here.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!